Bispecific Antibody Market By Drug Type (Blinatumomab, Catumaxomab, Duligotumab, Others), By Indication (Cancer, Infectious Disease, Inflammatory & Autoimmune Disorders, CNS Disorders, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Bispecific Antibody Market was valued at USD 1,715.9 million in 2022 and is poised to grow at a CAGR of 11.3% from 2023 to 2029. Bispecific antibodies are antibodies that are engineered in a way that it binds at two binding sites directed at two different antigens or two different epitopes on the same antigen. The bispecific antibodies have therapeutic effects superior to that of monoclonal antibodies with a broad application for tumor immunotherapy and treatment for other diseases.  The bispecific antibodies are evolving as the most commonly used and accurate method in the treatment of various types of cancer such as, lung cancer, prostate cancer, breast cancer, and colon. The increasing prevalence of cancer is expected to drive the market growth for the bispecific antibody market over the forecast period. For instance, according to the World Health Organization, about 18 million people deaths were registered due to cancer.

In addition, the development of new and innovative technologies, such as the use of antibody engineering and hybridoma technology is expected to propel the growth of bispecific antibody market. Furthermore, bispecific antibodies have greater specificity and affinity towards target cells leading to greater efficacy in treatment outcome and is expected to further fuel the growth of bispecific antibody market over the forecast period. However, high cost of bispecific antibodies along with regulatory challenges in conducting clinical trials is expected to hinder the growth of bispecific antibody market over the forecast period. Whereas factors like increasing demand for personalized medicines, growing application of bispecific antibodies in treatment of other diseases such as autoimmune disorder, infectious disease, and ophthalmology is expected to open up significant opportunities for the market players in the forecast period. Furthermore, ongoing clinical trials for the novel bispecific antibodies by pharmaceutical companies are expected to aid the growth of bispecific antibody market over the forecast period. 

Bispecific Antibody Market Key Developments:
  • In January 2023, the FDA approved Genentech’s bispecific antibody Glofitamab, CD20- and CD3-binding monoclonal antibody for the treatment of relapsed or refractory large B cell lymphoma.
  • In May 2023, AbbVie received the FDA approval for EPKINLY (epcoritamab-bysp) for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in adults.

Bispecific Antibody Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

11.3%

Largest Market

North-America

Fastest Growing Market

North America
Bispecific Antibody Market Dynamics

The bispecific antibody market is expected to grow over the forecasted period due to the increasing prevalence of cancer across the globe. Bispecific antibodies can target different antigens, including cancer cells, immune cells, and tumor microenvironment which helps in eliminating the cancer cells more efficiently. Furthermore, the bispecific antibody has shown improvement in clinical outcomes in the treatment of cancer patients, and bispecific antibody is approved by FDA for the treatment of lymphoblastic leukemia which has shown significant improvement in overall survival of patients compared to chemotherapy. Thus, these factors are expected to drive the growth of bispecific antibody market at a significant rate over the forecast period.

Key Features of the Reports

  • The bispecific antibody market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Bispecific Antibody Market Segmentation

By Drug Type
  • Blinatumomab
  • Catumaxomab
  • Duligotumab
  • Others
By Indication
  • Cancer
  • Infectious Disease
  • Inflammatory & Autoimmune Disorders
  • CNS Disorders
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Frequently Asked Questions

Bispecific Antibody Market was valued at USD 1,715.9 million in 2022 and is expected to grow at a 11.3% CAGR from 2023 to 2029.

The Bispecific Antibody market is segmented based on drug type, indication, distribution channel, and geography.

The leading players in the global bispecific antibody market are AbbVie, Celgene Corporation, Bristol Myers Squibb, Macro Genic, Calico, TG Therapeutics, Eli Lilly Corporation, Regeneron Pharmaceuticals Inc, Hoffmann-La Roche Ltd, Sanofi SA.

1.Executive Summary
2.Global Bispecific Antibody Market Introduction 
2.1.Global Bispecific Antibody Market  - Taxonomy
2.2.Global Bispecific Antibody Market  - Definitions
2.2.1. By Drugs Type
2.2.2. By Indication
2.2.3. By Distribution Channel
2.2.4. By Region
3.Global Bispecific Antibody Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Bispecific Antibody Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Bispecific Antibody Market  By Drugs Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Blinatumomab
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Catumaxomab
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Duligotumab
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Bispecific Antibody Market  By Indication, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Infectious Disease
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Inflammatory & Autoimmune Disorders
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. CNS Disorders
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Bispecific Antibody Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital Pharmacy
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacy
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacy
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Bispecific Antibody Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Bispecific Antibody Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Drugs Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Blinatumomab
9.1.2.Catumaxomab
9.1.3.Duligotumab
9.1.4.Others
9.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Cancer
9.2.2.Infectious Disease
9.2.3.Inflammatory & Autoimmune Disorders
9.2.4.CNS Disorders
9.2.5.Others
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacy
9.3.2.Retail Pharmacy
9.3.3.Online Pharmacy
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Bispecific Antibody Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drugs Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Blinatumomab
10.1.2.Catumaxomab
10.1.3.Duligotumab
10.1.4.Others
10.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Cancer
10.2.2.Infectious Disease
10.2.3.Inflammatory & Autoimmune Disorders
10.2.4.CNS Disorders
10.2.5.Others
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacy
10.3.2.Retail Pharmacy
10.3.3.Online Pharmacy
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Bispecific Antibody Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drugs Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Blinatumomab
11.1.2.Catumaxomab
11.1.3.Duligotumab
11.1.4.Others
11.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Cancer
11.2.2.Infectious Disease
11.2.3.Inflammatory & Autoimmune Disorders
11.2.4.CNS Disorders
11.2.5.Others
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacy
11.3.2.Retail Pharmacy
11.3.3.Online Pharmacy
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Bispecific Antibody Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drugs Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Blinatumomab
12.1.2.Catumaxomab
12.1.3.Duligotumab
12.1.4.Others
12.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Cancer
12.2.2.Infectious Disease
12.2.3.Inflammatory & Autoimmune Disorders
12.2.4.CNS Disorders
12.2.5.Others
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacy
12.3.2.Retail Pharmacy
12.3.3.Online Pharmacy
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Bispecific Antibody Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drugs Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Blinatumomab
13.1.2.Catumaxomab
13.1.3.Duligotumab
13.1.4.Others
13.2.  Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Cancer
13.2.2.Infectious Disease
13.2.3.Inflammatory & Autoimmune Disorders
13.2.4.CNS Disorders
13.2.5.Others
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacy
13.3.2.Retail Pharmacy
13.3.3.Online Pharmacy
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Ablynx
14.2.2.Adimab
14.2.3.Affimed Therapeutics
14.2.4.Amgen
14.2.5.AstraZeneca (MedImmune)
14.2.6.Chugai Pharmaceutical
14.2.7.EMD Serono
14.2.8.Emergent BioSolutions
14.2.9.Genentech
14.2.10.Genmab
14.2.11.Immunomedics
14.2.12.Jounce Therapeutics
15. Research Methodology 
16. Appendix and Abbreviations 
  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • NovImmune
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi

Adjacent Markets